Animation explaining the MOA of ACU193, a monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers for the treatment of early Alzheimer’s disease.
Copyright © 2022, Acumen Pharmaceuticals, Inc.


Client: Acumen Pharmaceuticals, Inc., (Charlottesville, VA, USA).

You may also like

Back to Top